Stock Analiz

Syndax Pharmaceuticals Inc SNDX

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$9.45Market cap $850M
Open the interactive analysis →

Syndax Pharmaceuticals Inc (SNDX) is a healthcare company listed in the US with a market value of about $850M. In the twelve months to September 30, 2026 it had revenue of $290M and net income of -$209M, a net margin of -72.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 158% a year, a 5-year average ROIC of -27%.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $627000 in 2015 to $172M in 2025, growth of about 75.4% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 43% over three years (dilution for shareholders). It spends 150% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.9
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-20.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)627.8%
Revenue growth (5 yrs, per year)157.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-498.0%
ROIC (5-yr avg.)-26.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$290M$172M$24M$0$0$140M$2M$2M$2M$2M$1M
Net income-$209M-$285M-$319M-$209M-$149M$25M-$73M-$56M-$74M-$61M-$44M
Free cash flow-$177M-$323M-$275M-$161M-$134M$29M-$71M—-$69M-$47M-$35M
EPS (diluted)$-2.36$-3.29$-3.72$-2.98$-2.46$0.46$-1.87$-1.84$-2.92$-2.90$-3.22
Net margin-72.3%-165.6%-1346.1%——17.8%-4822.5%-3694.6%-4875.5%-2884.3%-3645.2%
ROIC—-51.8%-28.0%-32.7%-25.6%4.8%-20.7%-139.9%-110.3%-46.9%-41.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $35.45, 275% above the current price; targets range from $17.00 to $57.00; the consensus rating is “Strong buy”; expected EPS is $-2.13 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Syndax Pharmaceuticals pay a dividend?

Not currently.

Is Syndax Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Syndax Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.